tirzepatide court ruling compound case Breaking News: Compounding Pharmacies Take the Fight to the Fifth Circuit The FDA's tirzepatide decision creates uncertainty – will they stop making tirzepatide

This change is not merely psychological GLP-1 receptor agonists may influence central appetite and reward pathways

Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications

besides, kidney protection with GLP-1 RAs has largely been demonstrated in large RCTs with longer follow-up durations

It notes GLP-1 therapy already slows gastric emptying and depends on adequate hydration, so adding an NSAID may raise upset stomach risk and complicate fluid intake monitoring during acute illness